Synergistic interactions between cannabinoid and opioid analgesics

Life Sciences

Volumn 74, Issue 11, 2004, Pages 1317-1324

  Cichewicz, Diana L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Analgesia; Cannabinoid; Opioid; Synergy

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANALGESIC AGENT; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; CODEINE; DEACETYLLEVONANTRADOL; DELTA OPIATE RECEPTOR; DIAMORPHINE; DRONABINOL; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ETORPHINE; FENTANYL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; LEVONANTRADOL; METHADONE; MORPHINE; NALOXONE; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; PENTAZOCINE; PERTUSSIS TOXIN; PETHIDINE; RIMONABANT;

AGGRESSIVENESS; ANALGESIC ACTIVITY; ANIMAL MODEL; ANXIETY; ATAXIA; BEHAVIOR; BRAIN; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; EUPHORIA; EXPERIMENT; HEADACHE; HUMAN; MODULATION; NOCICEPTION; NONHUMAN; PAIN; RECEPTOR BLOCKING; REVIEW; RIGHTING REFLEX; SIDE EFFECT; SIGNAL PROCESSING; SPINAL CORD; TACHYCARDIA; XEROSTOMIA;

ANIMALIA; CANNABIS SATIVA;

EID: 0346099153     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.09.038     Document Type: Review

References (50)

1. Allen K.V., McGregor I.S., Hunt G.E., Singh M.E., Mallet P.E. Regional differences in naloxone modulation of Δ9-THC induced Fos expression in rat brain. Neuropharmacology. 44:2003;264-274.
2. Beal J.E., Olson R., Lefkowitz L., Laubenstein L., Bellman P., Yangco B., Morales J.O., Murphy R., Powderly W., Plasse T.F., Mosdell K.W., Shepard K.V. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management. 14:1997;7-14.
3. Campbell F.A., Tramer M.R., Carroll D., Reynolds D.J., Moore R.A., McQuay H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. British Medical Journal. 323:2001;13-16.
4. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement of μ opioid antinociception by oral Δ9-tetrahydrocannabinol: dose-response analysis and receptor identification. Journal of Pharmacology and Experimental Therapeutics. 289:1999;859-867.
5. Cichewicz D.L., Haller V.L., Welch S.P. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with Δ9-tetrahydrocannabinol and morphine. Journal of Pharmacology and Experimental Therapeutics. 297:2001;121-127.
6. Cichewicz D.L., McCarthy E.A. Antinociceptive synergy between Δ9-tetrahydrocannabinol and opioids after oral administration. Journal of Pharmacology and Experimental Therapeutics. 304:2003;1010-1015.
7. Cichewicz D.L., Welch S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Δ9-THC. Journal of Pharmacology and Experimental Therapeutics. 305:2003;812-817.
8. Corchero J., Avila M.A., Fuentes J.A., Manzaneres J. Delta 9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sciences. 61:1997;L39-L43.
9. Fowler C.J., Jonsson K.O., Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochemical Pharmacology. 62:2001;517-526.
10. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
11. Fuentes J.A., Ruiz-Gayo M., Manzanares J., Vela G., Reche I., Corchero J. Cannabinoids as potential new analgesics. Life Sciences. 65:1999;675-685.
12. Ghosh P., Bhattacharya S.K. Cannabis-induced potentiation of morphine analgesia in rat: role of brain monoamines. Indian Journal of Medical Research. 70:1979;275.
13. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. Heterodimerization of μ and δ opioid receptors: a role in opiate synergy. Journal of Neuroscience. 20:2000;RC110.
14. Gutstein H.B., Mansour A., Watson S.J., Akil H., Fields H.L. Mu and kappa opioid receptors in periaqueductal gray and rostral ventromedial medulla. Neuroreport. 9:1998;1777-1781.
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience. 11:1991;563-583.
16. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Research. 822:1999;17-25.
17. Horan P., Tallarida R.J., Haaseth R.C., Matsunaga T.O., Hruby V.J., Porreca F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Sciences. 50:1992;1535-1541.
18. Johnson M.R., Melvin L.S., Althuis T.H., Bindra J.S., Harbert C.A., Milne G.M., Weissman A. Selective and potent analgetics derived from cannabinoids. Journal of Clinical Pharmacology. 21(8-9 Suppl.):1981;271S-282S.
19. Kuhar M.J., Pert C.B., Snyder S.H. Regional distribution of opiate receptor binding in monkey and human brain. Nature. 245:1973;447-450.
20. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. Journal of Pharmacology and Experimental Therapeutics. 276:1996;585-593.
21. Lichtman A.H., Martin B.R. The selective cannabinoid antagonist SR141716A blocks cannabinoid-induced antinociception in rats. Pharmacology Biochemistry and Behavior. 57:1997;7-12.
22. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding autoradiography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
23. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid receptors. Trends in Neurosciences. 11:1988;308-314.
24. Manzaneres J., Corchero J., Romero J.J., Fernandez-Ruiz J.A., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences. 20:1999;287-294.
25. Mason D.J., Lowe J., Welch S.P. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. European Journal of Pharmacology. 378:1999;237-248.
26. Massi P., Vaccani A., Romorini S., Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. Journal of Neuroimmunology. 117:2001;116-124.
27. Mechoulam R., Lander N., Srebnik M., Zamir I., Breuer A., Shalita B., Dikstein S., Carlini E.A., Leite J.R., Edery H., Porath G. Recent advances in the use of cannabinoids as therapeutic agents. Agurell S., Dewey W., Willette R. The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects. 1984;777-793 Academic Press, New York.
28. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesic circuit activated by cannabinoids. Nature. 395:1998;381-383.
29. Navarro M., Carrera M.R.A., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., Rodriguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience. 21:2001;5344-5350.
30. Nelson K.A., Walsh T., Deeter P. A phase II study of delta-9 tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Journal of Pallative Care. 10:1994;14-19.
31. Noyes R., Brunk S.F., Avery D.H., Canter A. The analgesic properties of delta-hydrocannabinol and codeine. Clinical Pharmacology and Therapeutics. 18:1975;84-89.
32. Pan Z.Z., Tershner S.A., Fields H.L. Cellular mechanism for anti-analgesic action of agonists of the kappa opioid receptor. Nature (London). 389:1997;382-385.
33. Pugh G. Jr., Smith P., Dombrowski D., Welch S.P. The role of endogenous opioids in enhancing the antinociception produced by the combination of Δ9-THC and morphine in the spinal cord. Journal of Pharmacology and Experimental Therapeutics. 279:1996;608-616.
34. Reche I., Fuentes J.A., Ruiz-Gayo M. Potentiation of Δ9- tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptors. European Journal of Pharmacology. 318:1996;11-16.
35. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and μ-opioid co-localization on postsynaptic target in the rat dorsal horn. Neuroreport. 12:2001;3689-3692.
36. Sawynok J. Topical and peripherally acting analgesics. Pharmacological Reviews. 55:2003;1-20.
37. Shapira M., Gafni M., Sarne Y. Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation. Brain Research. 960:2000;190-200.
38. Shapira M., Vogel Z., Sarne Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cellular and Molecular Neurobiology. 20:2003;291-304.
39. Smith F.L., Cichewicz D., Martin Z.L., Welch S.P. The enhancement of morphine antinociception by Δ9-tetrahydrocannabinol. Pharmacology Biochemistry and Behavior. 60:1998;559-566.
40. Smith P.B., Martin B.R. Spinal mechanisms of delta-9- tetrahydrocannabinol-induced analgesia. Brain Research. 578:1992;8-12.
41. Smith P.B., Welch S.P., Martin B.R. Interactions between Δ9-tetrahydrocannabinol and kappa opioids in mice. Journal of Pharmacology and Experimental Therapeutics. 268:1994;1382-1387.
42. Timpone J.G., Wright D.J., Li N., Egorin M.J., Enama M.E., Mayers J., Galetto G. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research, Human Retroviruses. 13:1997;305-315.
43. Vaught J.L., Rothman R.B., Westfall T.C. Mu and delta receptors: their role in analgesia and in the differential effects of opioid peptides on analgesia. Life Sciences. 30:1982;1443-1455.
44. Ware M.A., Doyle C.R., Woods R., Lynch M.E., Clark A.J. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 102:2003;211-216.
45. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. Journal of Pharmacology and Experimental Therapeutics. 262:1992;10-18.
46. Welch S.P. Modulation of cannabinoid-induced antinociception by nor-binaltorphimine, but not ICI 174,864, in mice. Journal of Pharmacology and Experimental Therapeutics. 265:1993;633-640.
47. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. Journal of Pharmacology and Experimental Therapeutics. 272:1995;310-321.
48. Welch S.P. Characterization of anandamide-induced tolerance: comparison to Δ9-THC-induced interactions with dynorphinergic systems. Drug and Alcohol Dependence. 45:1997;39-45.
49. Welch S.P., Eades M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Research. 848:1999;183-190.
50. Zimmer A., Valjent E., Konig M., Zimmer A.M., Robledo P., Hahn H., Valverde O., Maldonado R. Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. Journal of Neuroscience. 21:2001;9499-9505.